Related Experiment Video

Updated: Mar 6, 2026

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

9.3K

Cardio-oncology Related to Heart Failure: Epidermal Growth Factor Receptor Target-Based Therapy

Benjamin Kenigsberg1, Varun Jain1, Ana Barac1

  • 1MedStar Washington Hospital Center, MedStar Heart and Vascular Institute, Washington, DC, USA.

Heart Failure Clinics
|March 11, 2017
PubMed

Insights

Targeted cancer therapies like EGFR/ErbB/HER inhibitors can cause heart problems. This review covers their cardiotoxicity, mechanisms, and clinical cardio-oncology challenges.

Area of Science:

  • Oncology
  • Cardiology
  • Pharmacology

Background:

  • Epidermal growth factor receptor (EGFR)/ErbB/HER tyrosine kinase inhibitors are vital cancer therapeutics.
  • ErbB pathways are crucial for maintaining cardiac homeostasis.
  • These targeted therapies can lead to significant cardiotoxicity.

Purpose of the Study:

  • To summarize current knowledge on EGFR/ErbB/HER receptor-targeted cancer therapeutics.
  • To focus on their cardiotoxicity profiles and molecular mechanisms.
  • To discuss implications for clinical cardio-oncology and identify research opportunities.

Main Methods:

  • Literature review of EGFR/ErbB/HER targeted cancer therapeutics.
  • Analysis of cardiotoxicity profiles and molecular mechanisms.
  • Discussion of clinical cardio-oncology challenges and future directions.

Main Results:

  • EGFR/ErbB/HER targeted therapies are effective against various malignancies but pose cardiac risks.
  • Molecular mechanisms linking ErbB signaling to cardiac dysfunction are being elucidated.
  • Clinical management of cardiotoxicity presents significant challenges.

Conclusions:

  • Understanding the cardiotoxicity of ErbB-targeted therapies is crucial for safe cancer treatment.
  • Predicting, monitoring, and treating cardiac dysfunction requires further research.
  • Interdisciplinary approaches in cardio-oncology are essential for patient care.
Keywords:
CancerCardiac therapiesCardiovascular toxicityEGFR signalingHER2 pathwaysHeart failureTargeted cancer therapeutics

More Related Videos

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

8.5K
Enhancing Chimeric Antigen Receptor-Extracellular Vesicles (CAR-EV) Technology: The Future of Cancer Therapy07:33

Enhancing Chimeric Antigen Receptor-Extracellular Vesicles (CAR-EV) Technology: The Future of Cancer Therapy

Published on: September 19, 2025

910

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
8.2K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.0K
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
608
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.3K
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
488
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.3K